Home
»
Press Room
»
Psoriasis Drugs Market Size To Reach $39.11Bn By 2030

Psoriasis Drugs Market Size To Reach $39.11 Billion By 2030

May 2025 | Report Format: Electronic (PDF)

Psoriasis Drugs Market Growth & Trends

The global psoriasis drugs market size is estimated to reach USD 39.11 billion by 2030, registering to grow at a CAGR of 10.94% from 2025 to 2030 according to a new report by Grand View Research, Inc. Rising disease awareness, an increasing number of reimbursement strategies for biologics, and advanced diagnostic and technological tools are likely to increase the adoption of psoriasis therapeutics.

Additionally, the expanding base of patients suffering from psoriasis is anticipated to fuel growth prospects. The exact causative factors for psoriasis are undetermined; however, certain genetic and environmental factors may trigger the disease onset. Most available treatments aim to decelerate disease progression by stopping the hyperproliferation of keratinocyte.

Psoriasis can be classified into five types: plaque, guttate, inverse, pustular, and erythrodermic. The types vary in terms of the site of disease and characterization of lesions. Erythrodermic psoriasis is the rarest and plaque psoriasis is the most prevalent type affecting patients all over the world.

The incidence rate of psoriasis has witnessed a gradual rise over the years across various geographical locations. This increase can be attributed to genetic and environmental triggers as well as lifestyle changes. The rise in prevalence rates could also be associated with declining response or developing resistance to therapies for disease control.

key Request a free sample copy or view report summary: Psoriasis Drugs Market Report

Psoriasis Drugs Market Report Highlights

Tumor necrosis factor inhibitors dominated the market and accounted for a share of 40.88% in 2024 as they effectively target the inflammatory pathways crucial to the disease, resulting in major enhancements.
The biologics segment dominated the market in 2024 with a share of 46.38% as they are highly selective to certain immune pathways in connection to psoriasis and massive improvements in disease management compared to traditional medicines.
The topical segment is expected to register a significant growth rate over the forecast period.
The parenteral segment dominated the market, accounting for a 41.58% share in 2024.
The hospital pharmacies segment accounted for a leading share of the psoriasis drugs industry in 2024.
North America psoriasis drugs market held a leading market position in 2024, accounting for 38.65% of the global share.

Psoriasis Drugs Market Segmentation

Grand View Research has segmented the global psoriasis drugs market based on class, treatment, route of administration, distribution channel, and region:

Psoriasis Drugs Class Outlook (Revenue, USD Million, 2018 - 2030)